CSF-1R

Leustroducsin C is a colony-stimulating factor (CSF) inducer that stimulates the production of CSF from bone marrow stromal cells. This compound plays a critical role in hematopoiesis by enhancing the proliferation and differentiation of blood cell lineages, making it useful for research applications in immunology and regenerative medicine. Its ability to modulate the bone marrow microenvironment can be leveraged for studies on cellular interactions and therapeutic responses in various hematological conditions.

Vimseltinib is a selective dual inhibitor of c-FMS (CSF-IR) and c-Kit, demonstrating IC50 values of less than 0.01 μM and 0.1-1 μM, respectively. This compound exhibits robust biological activity, making it a valuable tool for investigating signaling pathways involved in hematopoiesis and various pathologies such as cancer and inflammatory diseases. The oral bioavailability of Vimseltinib enhances its potential for in vivo studies and therapeutic applications.

Pimicotinib is a selective and orally active inhibitor of the Colony Stimulating Factor 1 Receptor (CSF1R), with an IC50 value of 19.48 nM as determined by the inhibition of ADP production. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research applications aimed at understanding tumor microenvironment interactions and immune modulation. Researchers can utilize Pimicotinib to explore CSF1R-mediated signaling in cancer biology and potential therapeutic strategies.

Pimicotinib hydrochloride is a selective inhibitor of the colony-stimulating factor 1 receptor (CSF1R), demonstrating an IC50 value of 19.48 nM in inhibiting ADP production. This compound exhibits notable anti-tumor activity, making it a valuable tool for research in cancer biology and immunotherapy. Its specificity for CSF1R provides insights into the modulation of macrophage activity in the tumor microenvironment.

OSI-930 is a potent inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck with IC50 of 80 nM, 9 nM, 8 nM, 15 nM, 41 nM and 22 nM, respectively.

Sulfatinib (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC50s of in a range of 1 to 24 nM.

Pexidartinib hydrochloride is a potent, orally active inhibitor of the colony stimulating factor 1 receptor (CSF1R) and c-Kit, demonstrating ATP-competitive activity with IC50 values of 20 nM and 10 nM, respectively. This compound exhibits selective inhibition, with 10- to 100-fold potency over other related kinases. Pexidartinib hydrochloride promotes apoptosis in affected cells and exhibits significant anti-cancer properties, making it a valuable tool for research in oncology and immunology.